Results 171 to 180 of about 23,835 (226)

Factors Influencing Herpes Zoster Vaccine Utilization Among Adults Aged 50 and Above Attending Primary Healthcare Center in Saudi Arabia: A Cross-Sectional Study. [PDF]

Cureus
Almakhdob M, Selim M, Abdalrouf A.
europepmc   +1 more source

Vaccinations: "not just for kids” [PDF]

, 2018
Michel, Jean-Pierre
core  

Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocol. [PDF]

BMC Infect Dis
Hentzien M, Bonnet F, Bernasconi E, Biver E, Braun DL, Munting A, Leuzinger K, Leleux O, Musardo S, Prendki V, Schmid P, Staehelin C, Stoeckle M, Walti CS, Wittkop L, Appay V, Didierlaurent AM, Calmy A.   +17 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Varicella–Zoster Vaccine for the Prevention of Herpes Zoster

New England Journal of Medicine, 2007
A 64-year-old man in good general health presents to his internist for a routine examination. In a large clinical trial, the varicella–zoster vaccine reduced the incidence of herpes zoster by 51% and the incidence of postherpetic neuralgia by 67%. Should he receive this vaccine?
David W, Kimberlin, Richard J, Whitley
openaire   +4 more sources

Herpes Zoster Following COVID-19 Vaccination

Journal of Drugs in Dermatology, 2021
Vaccination is an important intervention in preventing the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Messenger RNA (mRNA) vaccines from Pfizer™ and Moderna™ are the first to market in the United States, and while cutaneous adverse events have been reported in clinical trials for both of these vaccines, they ...
Eden, David, Angelo, Landriscina
openaire   +2 more sources